Austria’s Apeiron To Attack COVID-19 At Its Entry Point
Phase II Study Starts In Three European Countries
You may also be interested in...
Dozens of life science companies are working to find effective treatments for COVID-19. In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into some of the efforts that are under way on this front.
Changes in the EU in the standard of care for high-risk neuroblastoma has resulted in EUSA Pharma’s monoclonal antibody being approved by the European Commission under exceptional circumstances.
The privately owned Austrian biotech attracts GSK to a Phase I ARDS biologic.